Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic, Key Genomics Teaming on Ovarian Cancer Treatment Test

NEW YORK (GenomeWeb News) – Transgenomic said today that it will work with Key Genomics to develop a molecular test to help physicians find out which ovarian cancer patients will respond to a certain drug treatment.
 
The test will couple Key Genomics’ coexpression extrapolation, or COXEN, predictive algorithm with Transgenomic’s DNA mutation detection analysis technology to predict epithelial carcinoma of the ovary.
 
Transgenomic said that its mutation and analysis technologies will “complement and enhance” the COXEN algorithm, which uses genomic and pharmacological response data about cancer lines to generate molecular response signatures to specific anti-cancer agents. The companies aim for the test to provide optimal therapy recommendations based on the specific characteristics of a patient’s tumor.
 
Because ovarian cancers are often diagnosed only after the tumor has spread beyond the ovary, getting “the best therapeutics option as quickly as possible is a key factor in survival,” Transgenomic CEO Craig Tuttle said in a statement. Using the COXEN-derived test that distinguishes which patients will benefit from a certain therapy, Tuttle said, “we believe physicians will be able to quickly direct ovarian cancer patients towards appropriate lines of therapy.”

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.